Company Profile
Boehringer Ingelheim
— A privately held, family-owned company that makes both small molecules and biologics in-house and offers that manufacturing capability to others
Boehringer Ingelheim was founded in 1885.Non-listed and Family ManagementThe Pharmaceutical Company The sales of 2025 are €27,051 million, and the human drug is €22 billion, and the rest is animal medicine. DDSBioXcellence is a pharmaceutical company that creates drugs in the company.I have. This page is based on low。s and biopharmaceu。s. It is spread to double-specific antibody (T-cell enhancer), ADC, tumor-soluble virus, and protein decomposition in。tor. This article is based on the annual business performance, release and business description published by the company on the official website.
- In 30 seconds, Boehringer Ingelheim and DDS standing position
- About logo and company name
- Where is this company in the world of drug discovery and DDS?
- Company Size (Concise)
- Drug discovery and DDS resources
- Past Initiatives
- Future plans
- What is DDS?
- Collaboration mapping of drug discovery and DDS
- Technologies, Products and Services
- The risk of this company
- Glossary/Source/Ins ment and Source Response Table
1. Boehringer Ingelheim in 30 seconds and standing position in drug discovery and DDS
Ingelheim am RhineGlobal Headquarters
+Contract manufacturingBioXcellence
BiopharmaceuExpanded to double-specific antibodies and ADC viruses
Boehringer IngelheimPharmaceutical CompanyBut at the same timeContract manufacturing (CDMO type) business contracted to manufacture other biopharmaceu sI'm working FactsHome BioXcellence, the contract manufacturing division, is based in Germany, Vienna, Austria, and Fremont, California. It is published that we provide culture production by mammal cells and microorganisms for other companies. In other words, the development of new drugs and the manufacture of other drugs2 positions in one companyThis is the starting point when you see this company in drug discovery and DDS.
2. Logo and company name
Boehringer Ingelheim Technology Co., Ltd. In this article, we do not reproduce the generated image
The logo (SVG) used in the header of the company's official websiteHome img/boehringer_ingelheim_logo.svg Contact Us
It is displayed on the same dark background as the official website.
Note: The company name is in English. Boehringer IngelheimHome In Japanese, it is written as "Beringer Ingelheim". (It is according to the company's Japanese corporate name) Name of contract manufacturing Boehringer Ingelheim BioXcellence™ Comment We do not provide annual reports to US SECs (10-K or 20-F) due to non-listed shares.
Official Site:https://www.boehringer-ingelheim.com/3. Where is this company in the world of drug discovery and DDS?
In the modalities, Jardiance, Ofev and Hernexeos, which were released in 2025, were both the sales pillar and Jascayd.DrinksHome FactsHome "In addition to the established expertise of low- and biopharmaceu s, we will expand the next generation of modalities" In the cancer areaT-Cell Enhancer (Double-Specific Antibody)、Tumor-soluble virus、Cancer Treatment Vac、Protein degradation in dector、ADC、Cancer treatment with genetically modified bacteriaContact Us GLP-1 receptor agonist for injection once a week in obesity and metabolic areaServo DutidePhase 3 The mechanism of each technology is handled in the technical commentary of this series: antibody medicine and ADC, target protein decomposition, virus vector, peptide medicine and GLP-1, and CDMO.
4. Company Scope (Concise)
Items that are disclosed for non-listing are less than listed companies, and only the numbers published by the company are used here. The amount is Euro (Millions) Facts。
| Index | 2024 views | 2025 years | January to June 2026 |
|---|---|---|---|
| Group sales (€ million) | 26,796 | 27,751 | about 15,800 |
| Pharmaceuticals (€ million) | 21,928 | 22,733 | about 13,100 |
| Animal medicine (€ million) | 4,749 | 4,875 | about 2,600 |
| Jardiance | ― | 8.8 | 5.7 |
| R&D expenses (€ million) | 6,212 | 6,353 | ― |
| Research and development costs for human drugs (€10 billion) | ― | 5.8 | ― |
In January to June 2026, the company replaced the approximate number of financial results pages (euro billion) to millions. "-" indicates that there is no value of the same category in the document confirmed in this article.
Jardiance 2025 Group Salesabout 31.7%Sales of human drugabout 38.7% The calculation of this paperHome Jardiance is a partner withli Lilly, according to 10-K of LillyUntil December 31, 2028For partners FactsHome In addition, due to non-listing, sales of operating income, capital investment, and contract manufacturing business (BioXcellence) are not listed in this article. Undetermined / Future。
5. Drug discovery and DDS resources
| Resource Types | ||
|---|---|---|
| People (Research Center) | The largest research and development base in Germany, Beberach (circulatory, kidney, ophthalmology, immune, respiratory). Wien is a base for cancer research and Rydgefield, Connecticut, U.S.A., where biopharmaceuticals such as bispecific and multispecific antibodies are explored. Other subsidiaries in Kobe, Switzerland, Basel and Austria, Inc. | Facts |
| Number of Researchers | The number of R&D employees is not listed in the documents confirmed (about 54,300 employees) | Not confirmed |
| Gold (R&D) | R&D costs €6,353 million (2025, 22.9% of sales). €5.8 billion in human medicine, 27.4% of the same business sales | Facts |
| Gold (Manufacturing Equipment) | Announced to invest $100 billion in R&D and manufacturing by 2028 in the U.S. (December 2025). VIENNA’s large cell culture plant invests more than €7 billion (operated in 2021, the largest in its history) | Facts |
| Manufacturing capacity (contract manufacturing) | Bevelach: 15,000L x 16 units, Vienna: 18,000L x 9 mammal cells, 6,000L x 2 microorganisms, Fremont: 15,000L x 2 units and 2,000L x 2 units | Facts |
| ViraThe)eutics, NBE The)eutics (ADC, 2020), T3 Pharma (Bacterial Cancer Treatment, 2023) | Facts | |
| Introduction and Venture Investment | Servo Dutide is introduced from NZ Pharma. Expanded BIVF’s funding framework to €12.5 billion in 2018 | Facts |
| Collaboration with universities and research institutions | Cooperation with the University of Dundee (Research Center for Prof. Alessio Ciulli) in protein decomposition in enzymes. Provides funding for basic research on IMP pathology (IMP) in Vienna. The design of the Vienna Plant conducts fluid analysis with Hamburg-Harburg Technical University. | Facts |
| Public Funds | Acceptance of government research grants related to drug discovery and DDS is not listed in the primary document confirmed | Not confirmed |
6. Past Initiatives
| Time | Home | The meaning of drug discovery and DDS |
|---|---|---|
| 1885 years | Albert Boehringer founded in Nieder Ingel (currently Ingel am Line). | Independent family management since |
| June 15, 2011 | Started development of GLP-1/Glucagon double actuated peptides with Zealand’s SEC submission. | Introduction of injection drugs in the metabolic area from outside |
| January 2018 | Expanded BIVF’s funding framework to €2.5 billion | Investment in early stage bio-entities |
| Year 2018 | ViraTherapeuticsBecome a wholly owned subsidiary | Developed the technical foundation of the tumor-soluble virus VSV-GP. |
| Year 2020 | NBE Therapeutics | ADC Technology Base |
| October 6, 2021 | Large cell culture plant in Vienna (LSCC) was launched. The largest investment in the company’s history in excess of €7 billion. 48 units and total capacity 212,000L (explained production capacity 185,000L) | Increased production capacity of mammal cells by 30%. A statement that it is used for both in-house products and contract manufacturing |
| 2023 year | T3 Pharma | Technology to deliver drugs to tumors with genetically modified ercinary bacteria |
| August 8, 2025 | FDAHer)eosQuick approval (USA) | Oral kinase inhibitor for non-small cell lung cancer with HER2 mutations. Re-entered the cancer area for the first time in about 10 years. |
| October 2025 | FDAJascaydApproved with a specific lung ventilator (US). Approval of advanced pulmonary ventilator in December. | PDE4B |
| December 19, 2025 | U.S. Government Announces Agreement on Drug Pricing and Production. | Invests in US$100 billion by 2028 |
| April 28, 2026 | SYNCHRONIZE-1 | Double actuator of injection once a week results in a later stage |
Main Clinical Trials
| Test name (NCT number) | Phase | Main evaluation items | Results published (comparison contrast/point) |
|---|---|---|---|
| SYNCHRONIZE-1（NCT06066515） | Phase 3. 725 adults with obesity and overweight without diabetes (ClinicalTrials.gov: 726) 3.6mg or 6.0mg per week | Change rate of weight at 76 weeks, reduction or more. | Average 16.6% reduction at maximum (3.3% reduction in placebo), 76 weeks, estimation when continuing treatment |
| FIBRONEER-IPF（NCT05321069） | Phase 3. Adult of Special Lung bro | Changes in Effort Lung Capacity (FVC) as of 52 weeks | 18mg -106mL, 9mg -122mL (placebo -170mL), 52 weeks |
| Beamion-LUNG 1 | Phase 1b. Pre-treated HER2 mutations non-small cell lung cancer. | Performance | 71 players No comparison in single-group testing |
The results are based on the official announcement of the company and the content of the ClinicalTrials.gov program. This article does not recommend a specific drug, but does not inferior to other drugs. Please contact your doctor for treatment.
7. Future plans
2026MASH Phase 3 (LIVERAGE)
Contact UsAfter acquiring phase 3 data
$100 billionUS$10 billion
In the early 2026, the company announced that five new compounds entered clinical trials, including three phase 3 trials in the cancer area. The project contains about 80 projects, and in 2025, it contains more than 50 new ones. FactsJascayd is waiting for the approval of the European Pharmaceutical Agency (European Medicines Agency), and the approval period is. Undetermined / Future Comment
None of the following documents have been listed Undetermined / Future。
BioXcellenceSales and Customer NameCompanyAnnual investment/ MoreR&D expenses/Research & DevelopmentNumber of employees/ Servo DutideApplication period。
8. What is this company aiming for drug discovery and DDS?
This includes parts that the company does not directly state.Calculation in the range that can be read from primary informationand write with the basis.
| Read | Primary Information | |
|---|---|---|
| ModalitySelect from the mechanism of the disease | Explanation that the company itself is "starting and not sticking to modalities" | Facts |
| Large cell culture equipmentKeep uptime by filling both in-house products and contracts | Wien’s factory is compatible with many items and provides the same equipment network to other companies as BioXcellence. Explanation that the life of the factory is expected to be about 40 years, "It was built for future products that are still unknown" | |
| Looking back at Jardiance,Both injection and oral with obesity andContact Us | In addition to servo dutide (one injection per week), "multiple methods including oral treatment" is being studied. Jardiance has partnered with Lilly for approximately 30% of sales. | |
| Cancer areaRe-enter the technical foundations taken by acquisition | ViraThe (2018), NBE (2020), T3 Pharma (2023), and Hernexeos’ first cancer region re-entered for about 10 years. | |
| Non-listedLong-term research investmentto use | R&D expenses ratio 22.9%, 27.4% in human medicine. "Independent and long-term perspective" |
BioXcellence’s Vienna Plant was introduced by the former plant manager, “The lifetime of this kind of facility is about 40 years.Building a factory today for tomorrow's products"I have a statement of the purpose FactsHome The factory is designed for multi-items, as well as for simultaneous production of different products. Because it is difficult to fill this scale for 40 years only with our biopharmaceu , We maintain occupancy rate by flowing from other companies through contract manufacturing, and aim at when our new biopharmaceu growsThis article is written assuming how to use Undetermined / Future。
9. Collaboration mapping of drug discovery and DDS
10. Technologies, Products and Services
| Technology | Typical Products and Initiatives | Stage |
|---|---|---|
| Oral medicine (tablets) | Jardiance, Ofev, Hernexeos, Jascayd | Approved |
| Double actuator of injection once a week | Servo Dutide (peptide acting on glucagon/GLP-1 receptor). Zealandd from zealand Pharma | Phase 3 |
| 3 receptor peptide | BI 3034701(GLP-1・GIP・NPY2 receptor) | Phase 2 in mid 2026 |
| T-Cell Enhancer | An in-house developed IgG-type double-specific antibody base. Oktamig (DLL3×CD3) | Contact Us |
| Tumor-soluble virus | VSV-GP (from ViraThe)eutics) | Contact Us |
| ADC and Protein Decomposition Inductors | NBE The)eutics-derived protein decomposition in)tor (KRAS, etc.) | Research & Development |
| Cancer treatment with bacteria | Genetically modified E. coli strains on tumors and deliver the eutic substances (from T3 Pharma) | Research & Development |
| BioXcellence | Production of culture by mammal cells and microorganisms, aseptic filling into vials (liquid and freeze drying), technology transfer. From late clinical to commercial supply | As a business |
Facilities published by BioXcellence in Beberach15,000L x 16 unitsin Vienna18,000L x 9 unitsin Fremont15,000L×3 unitsHome It is composed mainly of stainless steel large culture tank. FactsHome Vienna’s factory has a mechanism to wash and sterilize without disassembling (CIP/SIP) and a dedicated lifter to carry heavy chromatography columns.Fast multi-item setup replacementThe design is explained. This large stainless steel facility is different from a single-use resin bag type culture tank. Home Plastic and packing materials that can withstand repeated cleaning and sterilization, and chromatography resin used for purification.The life span and regeneration affect the occupancy rate and cost. The company's material specifications are not disclosed.
In Vienna, Hamburg-Harburg Institute of Technology andFluid analysis using a transparent culture tankI used the process transfer model to examine the mixing state. FactsHome The larger the size, the more oxygen and nutrition in the tank depends on the state of the cells, so this is the part where technology differs between the equipment and the materials (instructions).
11. Risks that this company has
| Risks | ||
|---|---|---|
| Dependency on Jardiance | Approx. 30% of Group sales. The deadline for the major market in partnership with Lilly is December 31, 2028 | Facts |
| US Pharmacy Policy | Participate in discount sales through direct sales platform in agreement with the U.S. government. Impact of Price Drops in USA | Facts |
| Quick approval confirmation | Her eos is fast-approved based on response efficiency, and the continuous approval must indicate clinical benefits in the verification test | Facts |
| It is difficult to verify from outside | Non-listed, there is no legal annual report and the sales of profits, capital investments, and contract manufacturing by business are difficult to confirm from outside. | |
| Contract manufacturing and the arrangement of our own products | More biopharmaceu s can reduce the ability to turn into contract manufacturing | |
| Initial stage of new modality | Cancer treatment with tumor-soluble viruses, bacteria, and protein degradation in agents are not approved |
12. Glossary
- Contract manufacturing (CDMO)
- Business to develop and manufacture drugs from other companies. BioXcellence
- T-Cell Enhancer
- Double-specific antibodies that combine both cancer cells and immune T cells to attack cancer cells.
- Tumor-soluble virus
- A virus designed to in and destroy cancer cells and cause immune response.
- ADC
- Antibody drug complex. Connect antibodies to cancer cells.
- Protein degradation in dector
- Low s that mark the protein that causes the disease and break through the mechanism of decomposition of the cells themselves.
- Glycoprotein / GLP-1 Double Actuator
- Medicine that stimulates both glicagon receptors and GLP-1 receptors. Developed with obesity and MASH.
- Quick approval
- US FDA system. Quickly approve the evaluation item of the alternative and check the clinical benefits in the subsequent verification test.
- Effort Lung Capacity (FVC)
- You can use the air that you can evacuate at once. Indicators of progression of lung fibrosis.
- CIP・SIP
- A method to wash (CIP) and sterilize (SIP) on the spot without disassembling the equipment.
- N-1 Perfusion
- How to change the medium continuously in a culture tank in front of this culture and make high cell density.
Concept diagram of AI generation13. Source
- Boehringer Ingelheim Boehringer Ingelheim delivers late-stage products with two key launches, growing sales by 7.3% in a successful 2025 (March 25, 2026). Sales and R&D costs for 2025, Jardiance/Ofev sales, new products, number of employees, year of establishment. https://www.boehringer-ingelheim.com/about-us/who-we-are/2025-pipeline-key-product-launches-sales-growth
- Boehringer Ingelheim Facts and figures Table of sales (by business) and R&D expenses for 2023-2025. https://www.boehringer-ingelheim.com/annualreport/2025/facts-and-figures/
- Boehringer Ingelheim Our half-year financial results Sales from January to June 2026, Jardiance sales, new product status, pipeline development. https://www.boehringer-ingelheim.com/about-us/who-we-are/our-half-year-financial-results-2026
- Boehringer Ingelheim BioXcellence Our global network 3 bases and equipment composition of contract manufacturing. https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network
- Boehringer Ingelheim BioXcellence Our large-scale cell culture facility in Vienna 48 units, 212,000L, 30% increase, multi-item design, fluid analysis with university, and former plant manager. https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/cell-culture-plant-vienna-bioxcellence
- Boehringer Ingelheim Theologyeutic modalities and platforms Modality Policy, T-Cell Enhancer, VSV-GP, Protein Decomposition Inhibitor and Dundee University, NBE (2020), T3 Pharma (2023). https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/discovery-research/our-oncology-therapeutic-modalities-and-platforms
- Boehringer Ingelheim Ingelgel's global research and development network IMP funds to production bases, subsidiaries and IMPs, and established sites. https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-ingelheims-global-research-sites
- Boehringer Ingelheim Survodutide significant weight loss of 16.6%... in Phase III trial (April 28, 2026). SYNCHRONIZE-1 design and result, introduction from Zealand Pharma, BI 3034701. https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial
- Boehringer Ingelheim U.S. FDA grants accelerated approval to Boehringer's HERNEX®® (August 8, 2025). https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval
- Boehringer Ingelheim U.S. FDA approves Boehringer's JASCAYD® (nerandomilast tablets) ... (October 9, 2025). FIBRONEER-IPF https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/fda-approves-jascayd-nerandomilast-first-new-treatment-ipf-over-decade
- Boehringer Ingelheim Boehringer Ingel has been announced on December 19, 2025. $100 billion investment and capital investment in the United States. https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-agreement-us-government
- Boehringer Ingelheim BIVF funding more than doubled to 250 M€ https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/bivf-funding-more-doubled-250-meur
- Eli Lilly and Company Form 10K for the) year ended December 31, 2025 Jardiance partnership with Boehringer Ingel。 and deadline for major markets (December 31, 2028). https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm
- ClinicalTrials.gov NCT066515(SYNCHRONIZE-1) Phase 3, number of registrations and completion status. https://clinicaltrials.gov/study/NCT06066515
- Boehringer Ingelheim Official website (for confirmation of company profile and logo) https://www.boehringer-ingelheim.com/
- Boehringer Ingelheim Boehringer Ingelheim Vienna in Austria in 2021, biopharmaceutical production facility in Vienna, Austria (October 6, 2021). https://www.boehringer-ingelheim.com/about-us/who-we-are/inaugurationbiopharmaceuticalproductionfacilityvienna
- Zealand Pharma A/S Form 20-F/A for the year ended December 31, 2021 License Agreement with Boehringer Ingelheim (June 15, 2011). https://www.sec.gov/Archives/edgar/data/1674988/000110465922042831/zeal-20211231x20fa.htm
14. Response table of claims and sources
| Content | ||
|---|---|---|
| Founded in 1885, 54,300 employees | Facts | Source 1・7 https://www.boehringer-ingelheim.com/about-us/who-we-are/2025-pipeline-key-product-launches-sales-growth |
| Sales (by business), R&D and R&D expenses ratio of 2023 to 2025 | Facts | Source 2 https://www.boehringer-ingelheim.com/annualreport/2025/facts-and-figures/ |
| Jardiance €8.8 billion, Ofev €3.8 billion, R&D expenses for human medicine €5.8 billion (27.4%, pipeline 80 and more than 50 new products). | Facts | Source 1 https://www.boehringer-ingelheim.com/about-us/who-we-are/2025-pipeline-key-product-launches-sales-growth |
| Jardiance is about 31.7% of Group Sales, about 38.7% of Human Drugs | The calculation of this paper | )ulation of this paper (cal)d from the number of source 1 and 2) https://www.boehringer-ingelheim.com/annualreport/2025/facts-and-figures/ |
| Sales and Jardiance sales from January to June 2026, European supply of Hernexeos, Phase 3 start and new compounds | Facts | Source 3 https://www.boehringer-ingelheim.com/about-us/who-we-are/our-half-year-financial-results-2026 |
| BioXcellence’s three bases, equipment structure, and contract manufacturing services | Facts | Source 4 https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/our-global-network |
| Vienna Plant (48 units, 212,000L, 30% increase, multi-item design, CIP, SIP, fluid analysis with universities, and about 40 years of life) | Facts | Source 5 https://www.boehringer-ingelheim.com/partnering/boehringer-ingelheim-bioxcellence/newsroom/cell-culture-plant-vienna-bioxcellence |
| Operation of the Vienna Plant (October 6, 2021), investment of more than €7 billion, production capacity of 185,000L, use for both in-house products and contracts | Facts | Source16 https://www.boehringer-ingelheim.com/about-us/who-we-are/inaugurationbiopharmaceuticalproductionfacilityvienna |
| Modality Policy, T-Cell Enhancer, VSV-GP, Protein Decomposition Inhibitor and Dundee University, NBE (2020), T3 Pharma (2023), ViraTheurgy (2018). | Facts | Source 6 https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/discovery-research/our-oncology-therapeutic-modalities-and-platforms |
| IMP funds to areas, subsidiaries and IMPs of production bases and each base | Facts | Source 7 https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/boehringer-ingelheims-global-research-sites |
| Design and results of SYNCHRONIZE-1 of servo dutch, introduction from Zealand Pharma, BI 3034701, phase 2 study of oral treatment | Facts | Source 8/14 https://www.boehringer-ingelheim.com/us/human-health/metabolic-diseases/results-phase-iii-synchronize-1-obesity-trial |
| GLP-1/Glucagon double actuated peptide | Facts | Source17 https://www.sec.gov/Archives/edgar/data/1674988/000110465922042831/zeal-20211231x20fa.htm |
| Results of Her)eos Quick Approval (August 8, 2025) and Beamion-LUNG 1 | Facts | Source 9 https://www.boehringer-ingelheim.com/us/media/press-releases/hernexeos-zongertinib-tablets-gains-accelerated-approval |
| Design and Result of FIBRONEER-IPF with Jascayd Approval | Facts | Source10 https://www.boehringer-ingelheim.com/human-health/lung-diseases/pulmonary-fibrosis/fda-approves-jascayd-nerandomilast-first-new-treatment-ipf-over-decade |
| Agreement with US$100 billion investment (including US$100 billion investment) | Facts | Source11 https://www.boehringer-ingelheim.com/us/media/press-releases/boehringer-ingelheim-announces-agreement-us-government |
| Expansion of BIVF’s Funding Framework (2018) | Facts | Source12 https://www.boehringer-ingelheim.com/science-innovation/human-health-innovation/bivf-funding-more-doubled-250-meur |
| Lilly and Jardiance partners and deadlines in major markets | Facts | Reference13 https://www.sec.gov/Archives/edgar/data/59478/000005947826000013/lly-20251231.htm |
| Positioning of three types of drug discovery and DDS, as well as two types | The calculation of this paper | This article does not specify the company name. The company name is an example from the series of companies in this article. |
| BioXcellence sales and customer, annual capital investment, modalities R&D expenses, R&D personnel, and time of application for servo dutide | Undetermined / Future | Not specified in the primary document. Don't guess https://www.boehringer-ingelheim.com/about-us/who-we-are/2025-pipeline-key-product-launches-sales-growth |
| Stainless steel pipes, packing materials, chromatography resins, and large tanks for stainless steel equipment. | Undetermined / Future | It is a general technical commentary, not disclosure of material specifications of the company |
| Read that large equipment is filled with our own products to keep uptime and risk of equipment handling | Interpre of this paper from source 4 and 5 | |
| Read that you want to have both injection and oral with obesity and | Interpre of this paper from source 8 and 13 | |
| The cancer region reads to re-enter the technical foundations acquired, and the risk that new modality is the initial stage | Interpre of this paper from source 3 and 6 | |
| Risks that are difficult to verify externally by using non-listed for long-term research investments | Interpre of this article from Source 1 and 2 |
Last Updated:September 26, 2026/Troy Technical
Boehringer Ingelheim does not publish a legal annual report on a non-listed basis, so the figures are based on the results, releases, and business introductions published on the official website and the U.S. SEC submissions of the affiliated E-Lily, and the ClinicalTrials.gov. information. We do not use estimates and media-based numbers of survey companies. The "ulation" section is an interpretation that the article reads from the primary information and is not an announcement of the company. This article is not medical advice, but is not recommended to use certain drugs.